Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?
Iovance has a long way to go to get to a break-even point, but the company has been showing progress.
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
Wall Street may be overestimating these companies' potential.
Iovance Biotherapeutics ( IOVA ) Reports Q3 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +13.79% and -4.10%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies ( DVAX ) Surpasses Q3 Earnings Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +50.00% and -0.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics, Inc. ( STOK ) Reports Q3 Loss, Beats Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -20.37% and +69.03%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Arcturus Therapeutics ( ARCT ) Q3 Earnings Expected to Decline
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders - Iovance Biotherapeutics ( NASDAQ:IOVA )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance ( IOVA ) To Contact Him Directly To Discuss Their Options
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 ( c ) ( 4 )
SAN CARLOS, Calif., Oct. 17, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) ( "Iovance" or the "Company" ) , a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( "TIL" ) therapies for patients with ...
Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health
Is there a glimmer of hope for either of these underperforming healthcare companies?
Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire?
Investors have certainly seen explosive gains from shares of biopharma companies in similar situations.
IOVANCE ( IOVA ) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Iovance Biotherapeutics ( NASDAQ:IOVA )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance ( IOVA ) To Contact Him Directly To Discuss Their Options
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 ( c ) ( 4 )
SAN CARLOS, Calif., Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) ( "Iovance" or the "Company" ) , a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( "TIL" ) therapies for patients with ...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 ( c ) ( 4 ) - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN CARLOS, Calif., Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc.
Can This Beaten-Down Stock Bounce Back?
This biotech company is innovative, but the market demands more than that.
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) , a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( TIL ) therapies for patients with cancer, today announced that ...
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) , a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( TIL ) therapies for patients with cancer, today announced that ...
Iovance Biotherapeutics to Present at Upcoming Conferences - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN CARLOS, Calif., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. IOVA, a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( TIL ) therapies for patients with cancer, today announced that senior leadership ...
If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today
The company hasn't been popular among investors since winning its first FDA approval more than a year ago.
IOVA Stock Drops 6% on $350M Common Stock Offering
Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline.
Why Iovance Biotherapeutics Stock Got Mashed on Monday
The company announced a flotation of its common shares that is potentially quite dilutive.
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday - Amber International ( NASDAQ:AMBR ) , Ascentage Pharma Group ( NASDAQ:AAPG )
U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Monday. Shares of Keurig Dr Pepper Inc. KDP fell sharply during Monday's session after the company announced the acquisition of JDE Peet's. Keurig Dr Pepper shares dipped 7.8% to $32.38 on Monday.
1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street
Time is running out for the company to mount a comeback.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 ( c ) ( 4 )
SAN CARLOS, Calif., Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) ( "Iovance" or the "Company" ) , a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( "TIL" ) therapies for patients with ...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 ( c ) ( 4 ) - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN CARLOS, Calif., Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc.
Why Iovance Biotherapeutics Stock Was Climbing Today
One and a half years after getting the nod from the U.S. Food and Drug Administration, its Amtagvi moves forward in a neighboring country.
Intel, Plymouth Industrial REIT, Premier And Other Big Stocks Moving Higher On Tuesday - Heartland Express ( NASDAQ:HTLD ) , Intel ( NASDAQ:INTC )
U.S. stocks were mixed, with the Dow Jones index gaining more than 150 points on Tuesday. Shares of Intel Corporation INTC rose sharply during Tuesday's session after it was announced that Softbank will invest $2 billion in the company.
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Color Star Tech ( NASDAQ:ADD ) , Adecoagro ( NYSE:AGRO )
Shares of Palo Alto Networks, Inc. PANW rose sharply in pre-market trading as the company reported better-than-expected financial results for the fourth quarter of fiscal 2025 and issued strong guidance for fiscal 2026 after the market closed on Monday.
Iovance's Amtagvi® ( lifileucel ) Receives Health Canada Approval for Advanced Melanoma - Iovance Biotherapeutics ( NASDAQ:IOVA )
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc.
Iovance's Amtagvi® ( lifileucel ) Receives Health Canada Approval for Advanced Melanoma
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy ...
3 Stocks That Could Turn $1,000 Into $5,000 by 2030
All three of these companies are entering a period of what could produce unparalleled top- and bottom-line growth.
Why Iovance Biotherapeutics Stock Plummeted Today
The company's top line nearly doubled.
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.
Pinterest Posts Downbeat Q2 Earnings, Joins Twilio, Trade Desk And Other Big Stocks Moving Lower In Friday Pre-Market Session - Gray Media ( NYSE:GTN ) , Firefly Aerospace ( NASDAQ:FLY )
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Friday. Shares of Pinterest, Inc. PINS fell sharply in pre-market trading after the company reported worse-than-expected second-quarter adjusted EPS results.
Why Expedia Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Click Holdings ( NASDAQ:CLIK ) , BioVie ( NASDAQ:BIVI )
Shares of Expedia Group, Inc. EXPE rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates. Expedia reported second-quarter revenue of $3.79 billion, up 6% year-over-year.
Iovance Biotherapeutics ( IOVA ) Reports Q2 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Iovance ( IOVA ) Q2 Revenue Jumps 93%
Iovance Biotherapeutics ( NASDAQ:IOVA ) , a biotechnology company specializing in cell therapies for solid tumors, reported GAAP earnings on August 7, 2025. The standout news was a 93% year-over-year GAAP revenue growth compared to Q2 2024, driven by its Amtagvi T cell therapy, but both GAAP ...
MaxCyte, Inc. ( MXCT ) Reports Q2 Loss, Misses Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics ( HALO ) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Is Iovance Biotherapeutics Stock Due for a Big Rally?
The biotech stock has been picking up steam of late -- but will it last?
This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?
Even the average price estimate for this stock suggests it can soar, but not everyone's convinced.
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Arrowhead Pharma ( NASDAQ:ARWR ) , Abivax ( NASDAQ:ABVX )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of GE Vernova Inc. GEV rose sharply during Wednesday's session after the company posted better-than-expected second-quarter 2025 earnings and raised its full-year guidance.
This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside
Investing in penny stocks -- companies with share prices under around $5 apiece -- could lead to monster returns over the long run. The flip side is that these corporations tend to carry above-average risk. It's challenging to determine which penny stocks might go on to deliver excellent ...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 ( c ) ( 4 )
SAN CARLOS, Calif., July 18, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) ( "Iovance" or the "Company" ) , a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( "TIL" ) therapies for patients with ...
IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Iovance Biotherapeutics ( NASDAQ:IOVA )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance ( IOVA ) To Contact Him Directly To Discuss Their Options
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Blue Gold ( NASDAQ:BGL ) , FB Financial ( NYSE:FBK )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Tuesday. Shares of Simulations Plus, Inc SLP fell sharply in pre-market trading after the company reported downbeat third-quarter sales and cut its FY2025 EPS guidance.
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN CARLOS, Calif., July 15, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
SAN CARLOS, Calif., July 15, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) , a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( TIL ) therapies for patients with cancer, today announced ...
Levi & Korsinsky Reminds Iovance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 14, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ( "Iovance" or the "Company" ) IOVA of a class action securities lawsuit.
IOVA FINAL DEADLINE ALERT: Hagens Berman Alerts Iovance ( IOVA ) Investors to Today's Lead Plaintiff Deadline in Securities Class Action - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN FRANCISCO, July 14, 2025 ( GLOBE NEWSWIRE ) -- firm Iovance Biotherapeutics Inc. IOVA announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025.
